The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Nia Therapeutics announced the publication of the first in vivo validation of its wireless, implantable brain-computer ...

Experts note that implantable loop recorders are valuable for detecting infrequent arrhythmias and guiding anticoagulation decisions post-cryptogenic stroke or atrial fibrillation ablation, but due to ...

Doctors at Columbus Community Hospital now have a high-tech new tool that can help them diagnose irregular heart rhythms that may not show up during standard testing. The tool, called a cardiac loop ...

Background: A relaxation of the prohibition of scanning cardiac rhythm device patients is underway, largely because of the growing experience of safe scanning events at 1.5T. Magnetic resonance ...

Background: Recent data suggest that the true incidence of atrial fibrillation (AF) after patent foramen ovale (PFO) closure has probably been underestimated, and may differ according to the type of ...

Medtronic‘s study of Linq implantable cardiac monitor (ICM) devices in atrial fibrillation (AFib) patients offers important lessons for other device developers, says the cardiac electrophysiologist ...